Integrating eSAGE With EHR Data Using Machine Learning for the Early Detection and Monitoring of Cognitive Impairment in Individuals
Launched by DOUGLAS SCHARRE · Aug 24, 2023
Trial Information
Current as of August 19, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This is a retrospective and prospective record review trial for patients who are followed at the Center for Cognitive and Memory Disorders.
eSAGE assessment data (including cognitive data, behavioral data, timing data and other metadata) as well as varying amount of electronic health records (EHR) data will be collected on all eligible subjects. Machine learning techniques with feature selection will identify important EHR variables to determine what may be useful for the prediction of cognitive impairment.
Based on the EHR analysis additional questions will be added to the eSAGE to make ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Males and females 50 years of age and over who complete the eSAGE as part of their office visit at the Center for Cognitive and Memory Disorders.
- Exclusion Criteria:
- • None
About Douglas Scharre
Douglas Scharre is a leading clinical trial sponsor known for its commitment to advancing research in neurodegenerative diseases, particularly Alzheimer's disease and related disorders. With a robust portfolio of innovative studies, Dr. Scharre and his team focus on developing novel therapeutic strategies and enhancing patient care through rigorous clinical investigations. Their collaborative approach emphasizes patient-centered research, aiming to translate scientific discoveries into practical treatments that improve the quality of life for individuals affected by cognitive decline.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Columbus, Ohio, United States
Patients applied
Trial Officials
Douglas Scharre
Principal Investigator
Ohio State University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported